Commercialization of Gene Therapy: Case Studies and Future Prospects

William Anderson
University of California, Berkeley, USA

DOI:https://doi.org/10.5912/jcb2530

Abstract:

The gene therapy market has made progress as it has become a workable solution to certain genetic disorders, cancers and chronic diseases. This paper will examine key case studies such as Luxturna, Zolgensma, Kymriah, and Yescarta which have made major progress with respect to regulatory approval, pricing, and patient outcomes. These successes, however, have not been without challenges. High expenditure, complex regulations, and limited production capacity have made true commercialization very difficult. Despite these challenges, improvements in gene editing technologies, innovative payment systems, and efficient mass production techniques give reason for hope. With more resources and cooperation from all parties, gene therapy can change the face of medicine and provide curative care for many disorders. The ramifications of commercializing gene therapy reach beyond the realm of healthcare and impact economy, ethics as well as global health policies. The prospects are quite appealing, but the issues of cost, regulation, and accessibility barriers pose significant concern. Gene therapy can reshape the modern meat of healthcare resources to better serve millions around the globe with the right advancement, conscious collaborations, and effective regulations.